Press Release ‐Tokyo Future Style, Inc

November 4th 2016

Tokyo Future Style signs Distribution Agreement for Japan and Taiwan
with TropIQ Health Sciences, a Dutch Bio Venture Company

Tokyo Future Style, Inc (Tsukuba City, Japan) and TropIQ Health Sciences (Nijmegen, theNetherlands) are pleased to announce having signed an agreement for distribution ofTropIQ’s proprietary unique drug discovery methods related to the vector bone diseases likemosquito transmission, such as Malaria, Dengue etc., in Japanese and Taiwanese market.
Vector-borne diseases are infectious diseases
transmitted by insects such as mosquitoes, flies
and ticks. Together they threaten half of theworld’s population and cause more than 1 million
deaths annually. People in the poorest countries
are the most vulnerable. For example, malaria
leads to over 250 million clinical cases and causes 600,000 deaths per year, mainly children
under five years of age in sub-Saharan Africa. The disease is caused by a parasite and istransmitted by mosquitoes.
About another mosquitoes transmissible disease, Dengue infection, in 2014, two years ago,
there occurred more than 100 people infection case by the domestic mosquitoes in a central
park in Tokyo, that was really the new
threat in our history. Further, in Taiwan,every year, Dengue transmission bymosquitoes is one of the biggest
national social issue to be controlled by
the government.
TropIQ’s technology platform includes
facilities for semi-automated cell and parasite culture, a vector lab for entomologicalexperiments and liquid dispensing and state-of-the-art signal detection equipment. TropIQ
has developed a unique barcoded live insect screening technology for discovery of novelvector control agents (insecticides, repellents, attractants) and malariatransmission-blocking molecules.

Products and Services by TropIQ
TropIQ provides services and reagents to accelerate the research. These include:
1.

Barcoded microtiter-plate based live insect screening assays for discovery of vector
control agents and antimalarials

2.

Insecticide sensitivity screens in systemic and contact mode3.

Malaria life cycle fingerprinting. IC50 measurements against all P. falciparum stages,
including gametocytes, oocysts, sporozoites and liver stage parasites.

4.

Sensitive mix-and-measure immunoassays to determine malaria immune responses

5.

Supply of wildtype and transgenic GFP/luciferase parasite stages for assay
development and assay calibration

6.

Supply of monoclonal antibodies against various epitopes of sexual stage antigens(Pfs48/45, Pfs25, Pfs230)

Tokyo Future Style, Inc is selling TropIQ’s products (Monoclonal antibodies) and mediate
their contract service for the territory of Japan and Taiwan.

About TropIQ Health Sciences

TropIQ Health Sciences was founded in 2011 as a spin-off of the Radboud University
Nijmegen Medical Center in the Netherlands. TropIQ combines world-class parasitologicaland entomological expertise with state of the art drug discovery technologies. Through thiscombination, TropIQ is uniquely positioned to accelerate the development of novel
medicines, vaccines and vector control measures.
About Tokyo Future Style, Inc.
Tokyo Future Style, Inc. is an international trading and marketing company located in the Tokyoarea. TFS mission is to market and distribute novel and unique products and services fromforeign biotech companies to academic and government institutions, and to research anddevelopment laboratories of major pharmaceutical, diagnostic and biotech companies in Japanand Taiwan.

Contact for this article:

Takashi Endo /CEO+81-29-851-9222

Tokyo Future Style, Inc.
endo@tokyofuturestle.com